Ionis Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 78 to 81 Wednesday.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an 80 or better RS Rating as they launch their biggest climbs.
While now is not an ideal time to jump in, see if the stock goes on to offer and clear a proper buy point.
The company showed 0% earnings growth in its most recent report. Revenue rose 101%.
The company holds the No. 177 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte, Inhibrx Biosciences and Kiniksa Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
